Nearly nine months after slashing 25 percent of the company’s workforce, Iroko Pharmaceuticals is terminating more than 100 full-time and part-time employees.
ViiV Healthcare made regulatory submissions to the EMA and the U.S. FDA for a single-tablet, two-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen).
While data help manufacturers fix plant-floor problems and trace quality issues to their source, it also can prevent recalls. Why not proactively use data to attain an end-to-end view of operations so that product quality can be ensured while reducing recalls?
Dutch healthcare technology company Philips said Thursday it had reached deals with New York’s Memorial Sloan Kettering Cancer Center (MSK) and Utah-based Intermountain Healthcare for them to use its genomics platform for cancer research and treatment.
Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients
Roche announced U.S. FDA approval of the Ventana ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with the Novartis drug Zykadia (ceritinib). The Ventana ALK (D5F3) Assay is the only immunohistochemistry (IHC) test approved by the FDA as a companion diagnostic for Zykadia.
Biogen Inc.’s Spinraza secured European Union approval to treat spinal muscular atrophy (SMA), a leading genetic cause of death in infants.
Things are looking bright for tiny startup biotech Cellanyx as the company has made headway on revolutionizing precision diagnostic test for prostate cancer.
The European Commission granted marketing authorization for BioMarin Pharmaceutical’s Brineura for the treatment of tripeptidyl peptidase 1 (TPP1) deficiency.
Jon Ogg, writing for 24/7 Wall Street, looks at seven biopharma stocks that have the potential to double or more in value during 2017.
The white paper explores trends and market forces affecting organized provider groups (OPGs) and identifies opportunities for pharmaceutical manufacturers to partner with OPGs to develop mutually beneficial programs addressing areas of shared interest.